Searched for
LUPIN STOCK PERFORMANCE
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Stocks in news: HDFC Bank, ICICI Bank, RIL, Trent, Jio FinancialIndian markets are set for a dynamic start today. Investors will closely watch the Q4 results from banking giants HDFC Bank and ICICI Bank....
- Lupin shares in focus as USFDA inspection at Somerset facility concludes with no observationsEarlier in January, the company received the Establishment Inspection Report (EIR) from USFDA for its Pithampur Unit-1 manufacturing facili...
- Why investors should be more worried about Lupin than DRLMain focus area remains complex generics where other cos have an advantage
- Fall in Lupin post Nifty exit may be a chance to accumulate stockLupin has gained over 50 per cent in absolute terms since its inclusion in the Nifty in September 2012.
- Add Lupin Ltd. target Rs 815: ICICI DirectAdd Lupin Ltd. at a price target of Rs 815.
- Why Lupin fails to earn a premiumLupin's management believes that investor concerns over the prospects of the pharmaceutical industry have prevented the deserved re-rating ...
- It may take another quarter for Lupin to post a robust showMumbaibased pharma company Lupin has posted better-than-expected numbers after reporting dismal figures for four successive quarters.
- Rising local sales, strong drug pipeline may nurse Lupin back to healthAfter a stellar show in earlier years, where it grew an average 20 per cent annually , it has been difficult for Lupin to sustain growth.
- FDA nod for drugs crucial for Lupin, Dr Reddy’s LaboratoriesLupin posted its worst quarterly performance with a drop in growth in key markets like US and Japan, resulting in flat revenues and a 300-b...
- Lupin Pharma's India business a cause for concernLupin Pharma’s underperformance in the domestic market may rein in investors’ bullish stance on the share — a hitherto darling of the India...
- Rally in Lupin's stock a precursor to its March quarter resultsThanks to launch of limited competition products in the US, Lupin is going to be an industry out performer for the March quarter.
- Overweight on pharma sector, Lupin remains a buy: Lalit Thakkar, Angel BrokingPharma companies are showing good growth rates of at least 20% per annum and the stocks’ valuations also are quite reasonable.
- Lupin is a good long term stock: Deepak Mohoni"Lupin is an excellent long term stock with quite a few short term rallies and it has actually been one of the better performers."
- Heard on Street: Bank Nifty best performer, but Old Fox’s short-sellingSquaring up of short positions helped Bank Nifty emerge as the best performer among indices on Monday.
- Sharekhan sees 30% upside in LupinSharekhan has maintained a Buy recommendation on pharmaceutical major Lupin.
Load More
